title: Chronic angiotensin receptor blockade suppresses intracardiac angiotensin II in angiotensin II-infused rats.
abstract: Accumulation of angiotensin II (Ang II) in tissues is an Ang II-receptor-mediated process. In pigs, acute angiotensin receptor blockade (ARB) reduced the heart-to-plasma ratio of Ang II following acute infusion. However in rats, chronic ARB treatment increased heart Ang II levels, suggesting that a differential response to ARB treatment may exist in the mammalian heart. Furthermore, the changes in heart aldosterone following chronic ARB treatment are not well described. To address the discrepancy in heart Ang II concentrations following ARB treatment, three groups (n = 6) of rats were chronically studied: (1) control; (2) angiotensin II (Ang II; 80 ng/min for 28 d); and (3) angiotensin II + olmesartan (ARB; 10 mg/kg/d for 21 d). Ang II-infusion increased intracardiac Ang II by 40% (53 ± 2 versus 74 ± 6 fmol/g) and intrarenal Ang II over 2-fold (96 ± 6 versus 207 ± 14 fmol/g), and chronic ARB treatment decreased Ang II by 48% in the heart (50 ± 7 fmol/g) and over two-fold in the kidney (92 ± 7 fmol/g), suggesting that accumulation of Ang II in the heart is receptor-mediated as in the kidney. Ang II increased plasma aldosterone 2.5-fold (1.4 ± 0.1 versus 3.5 ± 1.2 nmol/L) and was exacerbated by ARB treatment (5.6 ± 1.0 nmol/L). Intracardiac aldosterone was exacerbated by ARB treatment (control: 2.2 ± 0.3; Ang II: 2.7 ± 1.1; ARB: 7.8 ± 1.7 pmol/g). Suppression of intracardiac Ang II with ARB is consistent with the existing view of Ang II-receptor-mediated uptake by tissues.
authors.affiliation: Division of Natural Sciences, University of California, Merced, CA 95343,  USA.
authors.forename: Debra
authors.initials: D
authors.lastname: Conte
authors.forename: Jose
authors.initials: J
authors.lastname: Viscarra
authors.forename: Akira
authors.initials: A
authors.lastname: Nishiyama
authors.forename: Rudy M
authors.initials: RM
authors.lastname: Ortiz
mesh_terms: D000450:Aldosterone / Q000097:blood / Q000378:metabolism; D000804:Angiotensin II / Q000378:metabolism* / Q000494:pharmacology; D047228:Angiotensin II Type 1 Receptor Blockers / Q000494:pharmacology*; D000818:Animals; D006321:Heart / Q000187:drug effects; D007093:Imidazoles / Q000494:pharmacology*; D007668:Kidney / Q000187:drug effects / Q000378:metabolism; D008297:Male; D009206:Myocardium / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D013777:Tetrazoles / Q000494:pharmacology*
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D007093:Imidazoles; D013777:Tetrazoles; D000804:Angiotensin II; D000450:Aldosterone; C437965:olmesartan
references.citation: Am J Physiol Regul Integr Comp Physiol. 2000 Mar;278(3):R781-9
references.pmid: 10712301
references.citation: Hypertension. 1995 Nov;26(5):733-7
references.pmid: 7591011
references.citation: Br J Pharmacol. 1997 May;121(1):134-40
references.pmid: 9146897
references.citation: Hypertension. 1999 Jan;33(1 Pt 2):340-6
references.pmid: 9931127
references.citation: Hypertension. 1996 Oct;28(4):669-77
references.pmid: 8843896
references.citation: J Lab Clin Med. 1993 Oct;122(4):404-11
references.pmid: 8228554
references.citation: Annu Rev Physiol. 1992;54:227-41
references.pmid: 1562174
references.citation: Am J Physiol. 1994 Aug;267(2 Pt 2):H844-52
references.pmid: 8067441
references.citation: Hypertension. 2003 Jul;42(1):31-8
references.pmid: 12771047
references.citation: Am J Physiol Renal Physiol. 2007 Nov;293(5):F1584-91
references.pmid: 17715265
references.citation: Biochem Biophys Res Commun. 1992 May 29;185(1):142-6
references.pmid: 1599449
references.citation: Endocr Rev. 2003 Jun;24(3):261-71
references.pmid: 12788798
references.citation: Am J Physiol Renal Physiol. 2007 Jul;293(1):F139-47
references.pmid: 17376762
references.citation: Am J Med. 2006 Nov;119(11):912-9
references.pmid: 17071154
references.citation: Am J Physiol. 1993 May;264(5 Pt 2):F891-8
references.pmid: 8388654
references.citation: Hypertension. 2002 Jul;40(1):28-33
references.pmid: 12105134
references.citation: Am J Physiol Renal Physiol. 2008 Feb;294(2):F293-302
references.pmid: 18045833
references.citation: J Am Soc Hypertens. 2009 May-Jun;3(3):184-91
references.pmid: 20161115
references.citation: Ann Intern Med. 2008 Jan 1;148(1):30-48
references.pmid: 17984482
references.citation: Regul Pept. 2006 Dec 10;137(3):140-6
references.pmid: 16928404
references.citation: Hypertension. 1992 Jul;20(1):67-73
references.pmid: 1618554
references.citation: Hypertens Res. 2002 Mar;25(2):271-8
references.pmid: 12047043
references.citation: Kidney Int. 2004 Jul;66(1):1-9
references.pmid: 15200407
references.citation: Am J Hypertens. 2007 Aug;20(8):907-16
references.pmid: 17679042
references.citation: Endocrinology. 1997 Feb;138(2):725-33
references.pmid: 9003008
references.citation: Hypertension. 1997 Jul;30(1 Pt 1):42-9
references.pmid: 9231819
references.citation: Hypertension. 2002 Jan;39(1):116-21
references.pmid: 11799089
references.citation: Hypertension. 1999 Apr;33(4):981-6
references.pmid: 10205234
references.citation: Hypertension. 1996 Mar;27(3 Pt 2):658-62
references.pmid: 8613220
references.citation: Hypertension. 2004 Apr;43(4):841-8
references.pmid: 14769808
references.citation: Mol Pharmacol. 1995 Oct;48(4):601-9
references.pmid: 7476884
references.citation: Endocrinology. 2004 Nov;145(11):4796-802
references.pmid: 15308609
references.citation: Jpn J Pharmacol. 2000 Sep;84(1):75-7
references.pmid: 11043457
references.citation: J Am Soc Nephrol. 2005 Mar;16(3):703-11
references.pmid: 15647337